Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma

Abstract

High-dose interleukin-2 (HD IL-2) has curative potential in metastatic melanoma (MM) and renal cell carcinoma (RCC). Radiotherapy (RT) kills cancer cells and induces immunomodulatory effects. Prospective trials exploring clinical and immunological properties of combined RT/HD IL-2 are still needed. We designed a phase II, single-arm clinical trial for patients with MM and RCC. The treatment schedule consisted of 3 daily doses of 6-12 Gy of RT to 1-5 non-index metastatic fields, before IL-2 at the first and third treatment cycle. HD IL-2 was administered by continuous infusion for 72 hours and repeated every 3 weeks for up to 4 cycles, thereafter every 4 weeks for a maximum of 2 cycles. The primary endpoint was the immunological efficacy of the combined RT/HD IL-2 treatment (assessed by IFN-γ ELISPOT). Nineteen out of 22 patients were evaluable for immunological and clinical response. Partial response occurred in 3 (15.7%) patients and stable disease was observed in 7 (36.8%). The disease control rate was 52.6% after a median follow up of 39.2 months. According to Common Terminology Criteria for Adverse Events 4.0 (CTCAE 4.0), the majority of toxicities were grade 1-2. Immunological responses were frequent and detected in 16 (84.2%) patients. Increased levels of IL-8 and IL-10 in melanoma, circulating effector memory CD4+ and intratumoral CD8+ T cells in both tumor types were detected after therapy. Overall the treatment was well tolerated and immunologically active. Immunomonitoring and correlative data on tumor and peripheral blood cell subsets suggest that this combination treatment could be a promising strategy for patients progressing after standard treatments.

Recent advances in immunotherapy and its combination therapies for advanced melanoma: a review

“…In addition, the combination of SBRT and high-dose IL-2 (600000 IU/kg) also showed satisfactory results, with ORR and DCR of 54% and 75%, respectively, in patients with metastatic melanoma ( 97 ). And the immune activity of this combination was further confirmed in a phase II experiment ( 101 ).…”

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

“…The efficacy of IL-2 as a cancer immunotherapy has been evaluated in various clinical trials. High-dose IL-2 demonstrates potential, inducing objective responses in up to 15% of patients with metastatic melanoma and RCC, with some patients achieving durable complete responses [ 7 , 10 , 91 , 155 , 156 ].…”

IL-2 immunotherapy rescues irradiation-induced T cell exhaustionin vivo

“…The combination of RT with immunotherapy using high-dose unmodified IL-2 has shown promising results in preclinical and phase I and II clinical trials [25][26][27][28][29] .…”